| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 19.21 | -0.07 (-0.36%) | 10.85 - 20.95 | 14.1 million (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 19.29 |
|---|---|
| Previous Close | 19.28 |
| Day's Range | 18.88 - 19.60 |
| Market Cap | 4.8B |
| Avg Volume (10 Day) | 11.5M |
| Price/Earnings (Trailing 12 Mo.) | 11.9x |
| Earnings Per Share (Trailing 12 Mo.) | 1.61 |
| Dividend Yield | 0.25 (2.60%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
PR Newswire - Friday 05/10/2013 2:45 PM ET
| WCRX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -7.81% | |
| Net Income Growth (1yr) | 30.76% | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | 8.40% | |
| Price/Sales | 1.97 |
| Company | Last | Change |
|---|---|---|
| Endo Health Solutions Inc | 34.38 | +3.21% |
| Pharmacyclics Inc | 84.89 | +1.16% |
| United Therapeutics Corp | 69.17 | +1.01% |
| Cubist Pharmaceuticals Inc | 49.51 | +1.81% |
| Dr.Reddy's Laboratories Ltd | 37.93 | -1.58% |
Data is delayed by at least 15 min.